Vol 7, No 4 (2021)
Review paper
Published online: 2022-03-29

open access

Page views 4861
Article views/downloads 173
Get Citation

Connect on Social Media

Connect on Social Media

Immune-mediated inflammatory disease patients in the era of COVID-19 — who, how and when to vaccinate against COVID-19

Olga Gumkowska-Sroka1, Karolina Nowak2, Przemysław Kotyla2
Rheumatol. Forum 2021;7(4):169-176.

Abstract

Patients with autoimmune diseases are a particularly vulnerable group, prone to developing infectious complications. At the same time, due to the immunosuppressive treatment of these patients, the use of vaccination may raise some concerns
as to its effectiveness and, above all, its safety. This article presents the current recommendations of scientific societies indicating the efficacy, safety and, in particular, the necessity of immunization in all patients with inflammatory rheumatic diseases. Special emphasis in this study is placed on the efficacy and safety of vaccination against COVID-19.

Article available in PDF format

View PDF Download PDF file

References

  1. Zhou P, et al. Yang X-L, Wang X-G, Hu B, Zhang L Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. BioRxiv 2020: 2020. 2001; 2022: 914952.
  2. Guan WJ, Ni ZY, Hu Yu, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–1720.
  3. Ashour HM, Elkhatib WF, Rahman MdM, et al. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020; 9(3).
  4. Xia S, Liu M, Wang C, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020; 17(7): 765–767.
  5. Masters PS. The molecular biology of coronaviruses. Advances in Virus Research. 2006; 66: 193–292.
  6. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020; 92(4): 424–432.
  7. McGonagle D, Sharif K, O'Regan A, et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmunity Reviews. 2020; 19(6): 102537.
  8. Crayne CB, Albeituni S, Nichols KE, et al. The Immunology of Macrophage Activation Syndrome. Front Immunol. 2019; 10: 119.
  9. Sallusto F, Lenig D, Förster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754): 708–712.
  10. Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 [Epub ahead of print].
  11. Croce E, Hatz C, Jonker EF, et al. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports. Vaccine. 2017; 35(9): 1216–1226.
  12. Mellet J, Pepper MS. A COVID-19 Vaccine: Big Strides Come with Big Challenges. Vaccines (Basel). 2021; 9(1).
  13. Pushparajah D, Jimenez S, Wong S, et al. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Adv Drug Deliv Rev. 2021; 170: 113–141.
  14. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021; 384(22): 2092–2101.
  15. Subesinghe S, Bechman K, Rutherford AI, et al. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. J Rheumatol. 2018; 45(6): 733–744.
  16. França IL, Ribeiro AC, Aikawa NE, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford). 2012; 51(11): 2091–2098.
  17. Ribeiro ACM, Guedes LKN, Moraes JCB, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011; 70(12): 2144–2147.
  18. Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol. 2014; 24(3): 511–516.
  19. Winthrop KL, Wouters AG, Choy EH, et al. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol. 2017; 69(10): 1969–1977.
  20. Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020; 202(2): 149–161.
  21. Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020; 5(10): 1185–1191.
  22. Ibarrondo FJ, Hofmann C, Fulcher JA, et al. Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. ACS Nano. 2021 [Epub ahead of print].
  23. Haidar G, Agha M, Lukanski A, et al. Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis. medRxiv. 2021.
  24. Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. Arthritis Rheumatol. 2021; 73(8): e30–e45.
  25. So Ho, Mak JWY, So J, et al. Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. Semin Arthritis Rheum. 2020; 50(5): 885–889.
  26. Landewé RBm, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020; 79(7): 851–858.